← FDA DRUG APPROVALS
FDA BLA · BLA761134
RYZNEUTA
efbemalenograstim alfa-vuxw
Sponsor: EVIVE BIOTECHNOLOGY
APPLICATION
BLA761134
TYPE
BLA
ORIGINAL APPROVAL
2023-11-16
LATEST ACTION
2023-11-16
ROUTE
SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
RYZNEUTAPrescription
EFBEMALENOGRASTIM ALFA-VUXW 20MG/ML · INJECTABLE · INJECTION
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.